Celularity inc.CELU.US Overview
CELU Overall Performance
CELU AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
CELU Current Performance
16.34%
Celularity inc.
3.13%
Avg of Sector
0.32%
S&P500
CELU Key Information
CELU Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
CELU Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
CELU Profile
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Price of CELU
CELU FAQ
When is CELU's latest earnings report released?
The most recent financial report for Celularity inc. (CELU) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CELU's short-term business performance and financial health. For the latest updates on CELU's earnings releases, visit this page regularly.
What is the operating profit of CELU?
According to the latest financial report, Celularity inc. (CELU) reported an Operating Profit of -9.28M with an Operating Margin of -51.18% this period, representing a decline of 169.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CELU's revenue growth?
In the latest financial report, Celularity inc. (CELU) announced revenue of 18.13M, with a Year-Over-Year growth rate of 49.7%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does CELU have?
As of the end of the reporting period, Celularity inc. (CELU) had total debt of 29.03M, with a debt ratio of 0.22. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does CELU have?
At the end of the period, Celularity inc. (CELU) held Total Cash and Cash Equivalents of 738K, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CELU go with three margins increasing?
In the latest report, Celularity inc. (CELU) did not achieve the “three margins increasing” benchmark, with a gross margin of 93.12%%, operating margin of -51.18%%, and net margin of -147.71%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CELU's profit trajectory and future growth potential.
Is CELU's EPS continuing to grow?
According to the past four quarterly reports, Celularity inc. (CELU)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CELU?
Celularity inc. (CELU)'s Free Cash Flow (FCF) for the period is 1.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 131.25% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of CELU?
The latest valuation data shows Celularity inc. (CELU) has a Price-To-Earnings (PE) ratio of -0.43 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.